Naxitamab (previously called humanized 3f8 or hu3F8), a humanized GD2‐binding monoclonal antibody (mAb),5 is approved in the USA for use in combination with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) for the treatment of patients with R/R HR neuroblastoma limited to bone and/or BM who have demonstrated a partial response, minor response, or stable disease to prior therapy. The gene discussed is CSF2; the disease is neuroblastoma.